Quantifying the risk of hematopoietic cell transplantation (HCT) related mortality for pediatric patients is challenging. The HCT specific comorbidity index (HCT-CI) has been confirmed as a useful tool in adults, but has not yet been validated in children. We conducted a retrospective cohort study of 252 pediatric patients undergoing their first allogeneic HCT between January 2008 and May 2009. Pre-transplant comorbidities were scored prospectively using the HCT-CI. Median age at transplant was 6 years (range 0.1-20) and median follow-up was 343 days (range 110-624). HCT-CI scores were distributed as follows: 0, n=139; 1-2, n=52; and 3+, n=61. The 1 year cumulative incidence of non-relapse mortality (NRM) increased (10%, 14% and 28%, respectively; p<0.01) and overall survival (OS) decreased (88%, 67% and 62%, respectively; p<0.01) with increasing HCT-CI score. Multivariate analysis showed that compared to score 0, those with scores of 1-2 and 3+ had relative risks of non-relapse mortality of 1.5 (95%CI 0.5-4.3, p=0.48) and 4.5 (95%CI 1.7-12.1, p<0.01) respectively. These results indicate that the HCT-CI score predicts NRM and OS in pediatric patients undergoing HCT and is a useful tool to assess risk, guide counseling in the pre-transplant setting and devise innovative therapies for the highest risk groups.
Introduction
Despite major advances in the field of hematopoietic cell transplant (HCT) in recent years, life-threatening complications still occur. Quantifying this risk of toxicity for individual patients is challenging, but essential for accurate pre-HCT counseling.
Without adequate means to gauge pre-HCT risk, it is difficult to determine the value of the therapy for individual patients and makes an accurate comparison of outcomes between centers challenging.
Several indices have been used to quantify the impact of different comorbidities on overall disease specific outcomes. The Charlson Comorbidity Index (CCI) is one such commonly used index which was developed by assigning weights to 19 chronic conditions according to their association with one year mortality. A subsequent validation cohort confirmed that there was a stepwise increase in cumulative mortality with each increased comorbidity level. 1, 2 The CCI is frequently used in adults with a variety of chronic medical conditions and solid tumors, and has been used to predict non-relapse mortality (NRM) successfully in patients undergoing HCT. 3, 4 The sensitivity of the CCI in HCT patients is questionable, however, because many of the comorbidities included are rarely seen in HCT recipients and it misses many common HCT related comorbidities such as recent infections.
To further refine an index for HCT patients, Sorror et al developed the hematopoietic cell transplantation specific comorbidity index (HCT-CI). The HCT-CI is a modification of the CCI that incorporates more specific comorbidity definitions and the addition of
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From frequently seen HCT specific comorbidities. After retrospective testing and validation in over 1000 HCT patients, 17 comorbidities with a hazard ratio of >1.2 were included in the HCT-CI. A head to head comparison of the HCT-CI and CCI showed that the HCT-CI was more sensitive and a better predictor of NRM and OS in HCT patients. 5 Though some authors have questioned its universal applicability, 6,7 the HCT-CI has been subsequently validated with varying degrees of predictive ability in a number of independent adult HCT cohorts, including allogeneic, autologous, myeloablative (MA) reduced intensity conditioning (RIC) and nonmyeloablative (NMA) patients.
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The HCT-CI includes important comorbidities with varying effects on treatment related mortality and combines them into one score. It has been confirmed as a useful tool in adults, but has not yet been validated in children undergoing HCT. The aim of this analysis was to determine if the HCT-CI score accurately predicts outcomes in pediatric patients undergoing HCT. Table 2 for specific comorbidity definitions). At the time of the analysis, each patient's records were examined retrospectively in a uniform fashion by one site representative to confirm that all comorbidities were captured accurately. Excluding the mechanical ventilation and fungal infection history parameters, the comorbidities collected on the pre-TED form were then used to assign HCT-CI scores as originally described by Sorror et al. The adjusted hazard ratios (controlled for all coexisting comorbidities, age, conditioning intensity and disease risk) and integer weights previously published by these authors were used for scoring.
Materials and Methods
Comorbidities with an adjusted hazard ratio (HR) of 1.3 -2.0 (arrhythmia, cardiac, inflammatory bowel disease, diabetes, cerebrovascular disease, psychiatric disturbance,
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From mild hepatic, obesity and infection) were assigned a weight of 1, comorbidities with an adjusted HR of 2.1 -3.0 (rheumatologic, peptic ulcer, moderate/severe renal and moderate pulmonary) were assigned a weight of 2 and comorbidities with an adjusted HR of ≥ 3.0 (prior solid tumor, heart valve disease, severe pulmonary and moderate/severe hepatic) were assigned a weight of 3. The HCT-CI was the sum of these integer weights.
Patients then were assigned to one of three risk groups: low risk (score 0), intermediate risk (score 1-2) and high risk (score 3+). 5 Other transplant related and outcome data were collected retrospectively at each center.
The primary endpoints for this analysis were the cumulative incidence of NRM and probability of OS at one year post HCT. NRM was defined as death following HCT without disease progression or relapse.
Statistical Analysis: Kaplan-Meier curves were used to estimate the probability of OS and the cumulative incidence method was used to estimate the probability of NRM through two years post-transplant, treating relapse as a competing risk. 14, 15 The independent effect of the HCT-CI on OS and NRM was assessed by Cox regression and Fine and Gray models, respectively. 16, 17 All factors were tested for the proportional hazards assumption prior to inclusion in the models. Factors included in the regression models For personal use only. on October 3, 2017. by guest www.bloodjournal.org From donor versus umbilical cord blood) and center. All P-values were 2 sided. Analyses were performed using SAS 9.2 (SAS Institute) and R 2.4 statistical software. Tables 1 and 2 show demographic, treatment and comorbidity data by center. Underlying diagnoses included leukemia (n=110, 44%), immune deficiency (n=63, 25%), storage disorders (n=24, 9%), aplastic anemia (n=22, 9%), The most common comorbidities seen in our cohort were infection (n=18), pulmonary dysfunction (moderate, n=29; severe, n=12) and hepatic dysfunction (mild, n=40; moderate/severe, n=26). Peptic ulcer disease was not seen in our cohort. HCT-CI scores were distributed as follows: HCT-CI = 0 (n=139), 1-2 (n=52) and 3+ (n=61). The distribution varied significantly by center as seen in Table 1 .
Results

Patient Characteristics:
Non-Relapse Mortality:
Entire Cohort: The cumulative incidence of NRM at 1 year increased significantly with increasing HCT-CI score (HCT-CI score = 0: 10% [95% CI 5-15%], HCT-CI score = 1- (Table 4a) controlling for age, conditioning intensity, donor type and center showed that those with HCT-CI scores of 1-2 and 3+ had a relative risk of NRM of 2.2 (95%CI 0.3-16.7, p=0.44) and 10.2 (95%CI 1.3-82.6, p=0.03) when compared to those with a score of 0. Age and center had no effect on NRM. (Table 4b) Due to the small number of patients in this subgroup, a multivariate analysis was not performed.
Overall Survival:
Entire Cohort: The probability of OS at 1 year decreased significantly with increasing HCT-CI score (HCT-CI score = 0: 88% [95% CI 80-92%], HCT-CI score = 1-2: 67% Other factors affecting OS at one year included a prior history of mechanical ventilation (no, 78% vs. yes, 65%; p=0.02) and proven fungal infection (no, 78% vs. yes, 44%; p<0.01). A multivariate analysis (Table 3) controlling for age, conditioning intensity, donor type and center showed that those with HCT-CI scores of 1-2 and 3+ had a relative risk of death of 2.6 (95%CI 1.2-5.6, p=0.01) and 4.6 (95%CI 2.1-9.7, p<0.01) respectively when compared to those with a score of 0. Those receiving MA conditioning had a trend toward reduced OS. Age and center had no effect on OS. (Table 4a ) controlling for age, conditioning intensity, donor type and center showed that those with HCT-CI scores of 1-2 and 3+ had a relative risk of death of 3.1 (95%CI 1.4-7.0, p<0.01) and 4.6 (95%CI 1.9-11.0, p<0.01) respectively when compared to those with a score of 0. Age and center had no effect on OS.
All Patients Receiving MA HCT: In all patients receiving MA HCT, the probability of (Table 4a) 
age, conditioning intensity, donor type and center showed that those with HCT-CI scores of 1-2 and 3+ had a relative risk of death of 3.5 (95%CI 1.111.0, p=0.04) and 5.3 (95%CI 1.5-18.7, p<0.01) respectively when compared to those with a score of 0. Age and center had no effect on OS.
Patients Receiving RIC/NMA HCT: In patients receiving RIC/NMA HCT, the probability of OS at 1 year trended down with increasing HCT-CI score (HCT-CI score = 0: 93% [95% CI 74-98%], HCT-CI score = 1-2: 100% and HCT-CI score 3+: 71% [95% CI 46-86%]; p=0.09), though this was not statistically significant. Due to the small number of patients in this subgroup, a multivariate analysis was not performed.
Discussion
Since Sorror et al's original publication in 2005 outlining the predictive ability of the HCT-CI, many groups have sought to validate the scoring system in a variety of disease and donor specific settings.
6-12 None of these researchers focused on pediatric patients undergoing transplant. The variation in the predictive ability of the HCT-CI among adult cohorts exemplified the need to test the scoring system in pediatrics, another very unique population. This is the first paper to show that the HCT-CI scoring system predicts NRM and OS in pediatric patients undergoing allogeneic HCT and consequently, is a useful tool to assess risk, guide counseling and devise innovative therapies in the highest pediatric risk groups.
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From Our patient cohort was fairly heterogeneous in that it included pediatric patients with a variety of diagnoses who received both MA and RIC/NMA conditioning. Because previous reports have highlighted the variability in the predictive value of the HCT-CI by factors like disease and conditioning intensity, we also performed subanalyses in more homogenous groups (patients with hematologic malignancies receiving MA HCT, all patients receiving MA HCT and all patients receiving RIC/NMA HCT). The predictive ability of the HCT-CI was confirmed in both MA subgroups. Additionally, despite very limited numbers, there was a trend toward increasing NRM and decreasing OS with increasing HCT-CI score in the RIC/NMA subgroup. Larger analyses need to be performed in RIC/NMA patients to verify this trend. Overall, though, the predictive capability of the HCT-CI in pediatric patients appears to be generalizable.
Further refinement of the scoring system specifically for children, however, may be helpful given that 55% of the patients in our cohort had an HCT-CI score of 0 indicating that the scoring system lacks some sensitivity. This refinement could include an adjustment of the comorbidity definitions to better fit pediatric patients (e.g. more accurately define renal dysfunction using GFR or a multiple of the upper limit of normal serum creatinine rather than having a strict cut-off of serum creatinine >2mg/dL). The addition of other pediatric specific factors, like congenital heart disease or multiple congenital abnormalities as is seen in genetic conditions like Fanconi anemia or Hurler syndrome, could also be considered. This revised score would then need to be tested and validated in a larger population of pediatric HCT patients as Sorror et al did in their original study.
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For personal use only. on October 3, 2017. by guest www.bloodjournal.org From One limitation of this analysis is the difference in the number of comorbidities reported by each center. This could be secondary to a fundamental risk difference in the patient populations based on individual center expertise, conditioning intensity and donor type, or due to differences in pre HCT testing requirements at each center. For example, the utility of pulmonary function testing is controversial in pediatrics given that the results are dependent upon patient understanding, cooperation and effort. Only two of the four centers included in this analysis routinely do pulmonary function testing prior to transplant. As a result, these centers had a larger number of recorded pulmonary comorbidities. Despite a significantly different number of comorbidities between centers, though, each center had similar NRM rates leading us to believe that there was no confounding effect on the relationship between HCT-CI and NRM. Additionally, "center" was included as a factor in the regression analyses and was determined not to be a significant predictor or NRM or OS.
Another potential explanation for the difference in the number of comorbidities at each center is potential variability in how the individual scores were assigned by the treating physicians. In order to exclude this possibility, every patient's comorbidities were retrospectively reviewed and rescored in a uniform fashion by a designated person from each site. By doing this, a number of additional comorbidities were discovered at each site (total = +69; CCHMC = +11, DFCI/CHB = +27, UMACH = +17, TXCCC = +14).
The majority of the added comorbidities (53/69 or 77%) were in the hepatic and pulmonary categories. Potential reasons for initially overlooking these comorbidities
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include unfamiliarity of the transplant physician with the specific comorbidity definitions and the assumption that small elevations in transaminases or decreases in pulmonary function testing in otherwise well appearing children were not significant enough to note.
Regardless of the reason, our discovery of inconsistent scoring illustrates that this may be a common occurrence and these scores should be double checked for accuracy. In order for a comorbidity index to be accurate and useful, it needs to be applied consistently within and among centers.
In conclusion, HCT-CI score predicts NRM and OS in pediatric patients undergoing HCT based on data from 4 large pediatric transplant centers and may be used in the pre HCT setting to help quantify the risk of mortality from transplant related complications.
Refinement of the scoring system for pediatrics and subsequent prospective testing in larger populations may further increase its utility.
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